Appeal No. 2007-0531 Page 10
Application No. 10/341,679
5. replication defective recombinant adenoviral vectors may be
used as delivery vehicles for the DNA encoding the angiogenic
protein. Column 5, lines 51-64.
6. gene transfer on acute hindlimb ischemia, which comprises the
injection DNA encoding angiogenic protein into five different
sites in three major thigh muscles of a rabbit. The rate of each
injection was approximately 5 seconds, after completing 5
injections the skin was closed. Column 7, lines 45-65.
7. “that it may be desirable to use nucleic acids encoding two or
more different proteins in order to optimize the therapeutic
outcome. For example, DNA encoding two angiogenic proteins,
e.g., VEGF and bFGF can be used . . . .” Column 6, lines 4-8.
Isner does not teach:
1. VEGF121.
2. injection of an replication defective recombinant
adenoviral vector comprising VEGF121 DNA directly to the
internal surface of the heart.
Kovesdi teaches:
1. multiply replication deficient adenoviral vectors for use in gene
therapy. Column 5, lines 55-59 and column 7, lines 27-29.
2. “multiply replication deficient adenoviral vectors [that] can
accommodate the insertion and expression of larger fragments
of foreign DNA than is possible with singly replication deficient
adenoviral vectors. . . .” Column 5, lines 50-53.
3. that a preferred embodiment of the present inventive adenoviral
vector include[s, inter alia,] . . . E1- E4- . . . adenoviral vectors,
which can also be E3-.” Column 8, lines 35-38.
4. a multiply replication deficient adenoviral vector that “is deficient
in the E1, E3, and E4 regions.” Example 2, column 16, lines 31
-column 18, line 26.
5. the multiply replication deficient adenoviral vector
“AdGVCFTR.10” that “is deficient in the E1 and E3 regions.”
Example 1, column 15, line 45 – column 16, line 29.
Page: Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
Last modified: September 9, 2013